Muscatelli S, Zheng H, Hughes R, et al. - Between April 1, 2013, and December 31, 2018, researchers conducted a non-inferiority analysis of a retrospective cohort of patients undergoing total hip arthroplasty. Researchers recruited cases from the Michigan Arthroplasty Registry Collaborative Quality Initiative database and conducted by 355 surgeons at 61 hospitals throughout Michigan. The postoperative venous thromboembolism event or death and bleeding event were the primary endpoints. The study population consisted of 59,747 individuals, 32,878 (55.03%) were female, and the mean age was 64.5. The data exhibited that aspirin is not inferior to other anticoagulants as pharmacologic venous thromboembolism prophylaxis with regards to the postoperative risk of venous thromboembolism or bleeding. For venous thromboembolism prophylaxis, sole use of aspirin after total hip arthroplasty should be considered in the appropriate patient.